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ABSTRACT
In oncology, as in other clinical fields, different
treatments are often approved for the same therapeutic
indication. In many cases, no direct comparisons are
available to inform the choice in clinical practice. In
2015, the Italian Association of Medical Oncology
(AIOM) instructed a working group, including both
clinicians and methodologists, to discuss the issue of
the best choice among different treatments available
for the same indication. The working group
discussed 3 different scenarios: (1) biosimilar drugs;
(2) different drugs with same mechanism of action;
(3) different drugs with different mechanism of action.
For each scenario, methodological issues were
discussed, along with the priority for investment of
resources in the conduct of clinical trials testing direct
comparison. As for biosimilar drugs, the panel
recommended that, following comparability exercise
and approval by regulatory agencies, they should be
widely used, considered that their use allows financial
savings. As for different drugs (with either the same or
a different mechanism of action), the panel agreed that
indirect comparisons and network meta-analyses are
associated with relevant risk of bias and imprecision,
and direct comparisons should be encouraged. The
priority of these direct comparisons should be higher
when the potential differences in efficacy and/or
toxicity are clinically relevant. The choice of the
study design (superiority vs non-inferiority) depends
on the toxicity profiles and also on the presumed
difference in efficacy. Scientific societies should put
pressure on public bodies to identify all the
administrative and financial mechanisms useful to
facilitate the conduct of trials testing direct
comparisons, when needed. Decision about therapeutic
equivalence can have important consequences on
innovation: the availability of drugs characterised by
the same effectiveness, but at a lower cost, could
enable non-negligible savings of economic resources
that could be used to guarantee access to innovative,
high-cost drugs.
INTRODUCTION
In recent years, due to economic difficulties
(not limited to a single country but substan-
tially global, although with different severity
among countries), there has been a rapidly
growing awareness of the limitation of finan-
cial resources. As a consequence, the
concept of sustainability has gained a crucial
role in the scientific debate about the effi-
cacy of anticancer treatments.1 2
Testing a new treatment in a clinical trial is
primarily focused on demonstrating a favour-
able ratio between risks and benefits asso-
ciated with its administration. However, a
great deal of methodological rigour is
needed in the conduct and interpretation of
the clinical trials, in order to derive a more
complete picture of the value of the new
treatment for the patient and the society.3–5
In fact, the introduction of a treatment into
clinical practice involves the determination
of a price, and adopting the new treatment
represents a direct cost for the community.
Many opinions have recently invited to
‘raise the bar’ in the assessment of the effi-
cacy of experimental treatments in clinical
trials.3–5 This invitation, and the consequent
decisions, should fall on the central regula-
tory authority level, and not on the individ-
ual peripheral administrative centres.6 7 In
fact, if economic choices about drug reim-
bursement and availability in clinical practice
are taken at the highest decisional level,
unacceptable disparities could be avoided,
and the single physician, when discussing
with an individual patient, could avoid to put
financial considerations over and above clin-
ical arguments. Of course, this does not
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mean that doctors should not be aware of the cost of
the drugs: the economic implications of treatment deci-
sions should be always taken into account. Indeed, due
to the relevance of these topics, decision-making should
involve the contribution of all the stakeholders, the
doctors and even the patients themselves. The involve-
ment of patients in the debate should be greatly encour-
aged by the scientific societies, inasmuch as it would
impose on all involved parties the need to address the
critical issues related to the balance between treatment
advantages and costs. This would probably create a
stronger alliance between healthcare professionals and
patients, and would—in any case—increase awareness
among all parties.
In this complex debate, the concept of therapeutic
innovation should be clearly distinguished from the
issues related to therapeutic equivalence. In the case of
innovation, when a new therapeutic strategy has demon-
strated a greater efficacy compared with the previous
standard, the debate should centre on both the benefit–
risk ratio and on the size of the increase in efficacy.8–10
A shared and reproducible procedure should be identi-
fied to define how much the community is willing to pay
for benefits of various types and sizes. In any case, very
small benefits may be negligible, irrespective of the cost.
However, shared and reproducible procedures should be
also identified to define this minimal level of efficacy,
below which the incremental benefit could be consid-
ered as clinically not relevant. On the other hand, in the
case of therapeutic equivalence, the scientific debate is
centred on the choice between therapeutic options of
similar efficacy, for the same clinical indication. If the
tolerability profile roughly differs between these options,
toxicity will obviously play a determining role in the
choice. However, when the tolerability profile is also
similar, the cost may reasonably play a role in the choice
of one treatment over another. Of course, the equiva-
lence margin of efficacy must be sufficiently small so
that the cost-based choice can be scientifically and ethic-
ally transparent, and shareable with the patients. Of
note, decisions in the field of therapeutic equivalence
can have important consequences also on innovation:
the availability of drugs characterised by similar efficacy,
but at lower cost (typically, the case of biosimilar drugs),
could enable a non-negligible saving of economic
resources that could be used to guarantee access to
innovative, high-cost drugs.
Therefore, how to help the choice among different
treatments available for the same therapeutic indication?
In 2015, the Italian Association of Medical Oncology
(Associazione Italiana di Oncologia Medica, AIOM)
appointed a dedicated working group, including both
clinicians and methodologists, with the aim of discussing
the clinical and methodological aspects of this topic.
The panel produced a document, approved by the
AIOM National Directory and freely available on the
AIOM website.11 This paper summarises the conclusions
of the working group.
METHODS
The AIOM working group on therapeutic equivalence
was coordinated by a member of AIOM National Board
(MDM), and composed of three clinicians, with specific
expertise in different solid tumours (FM, MT and EV)
and three methodologists, with specific expertise in clini-
cal cancer research (PB, FP and VT). The group worked
by physical and virtual meetings, between January and
April 2015. The final document, endorsed by the AIOM
National Board, was published on the AIOM website in
April 2015. In September 2016, for the present publica-
tion, the original material was adapted, updated as
appropriate and revised by all the authors.
As a preliminary step, four potential scenarios of
therapeutic equivalence were identified, as reported in
table 1. Of the scenarios outlined in table 1, the AIOM
working group did not address scenario 1 (ie, the issue
of generic drugs). Coherently with issues discussed by
the working group, this paper is structured to address
the remaining three scenarios, that is, the issue of biosi-
milar drugs (table 1, scenario 2) and the issue of drugs
with a different active principle but approved for the
same therapeutic indication (table 1, scenario 3: drugs
with the same mechanism of action; scenario 4: drugs
with different mechanisms of action).
SAME THERAPEUTIC INDICATION, SAME MECHANISM OF
ACTION, BIOSIMILAR DRUGS
A biosimilar drug is a ‘copy’ version of an already
authorised drug (usually called ‘originator’) with similar
biological activity, physicochemical characteristics, effi-
cacy and safety.12 Not only in oncology, but in many clin-
ical fields, the development of biosimilar drugs has been
considered an opportunity in terms of resource
savings.13 14 The first setting where biosimilar drugs have
been available in cancer clinical practice is the ‘support-
ive care’ for patients undergoing chemotherapy (ie,
granulocyte colony-stimulating factors,15 erythropoiesis-
stimulating agents).16 However, as of 2016, biosimilar
drugs are soon awaited for several anticancer drugs
(monoclonal antibodies) that are currently indicated in
the treatment of patients with advanced disease (eg, tras-
tuzumab, bevacizumab, rituximab) or as adjuvant treat-
ment (eg, trastuzumab in the adjuvant treatment of
early breast cancer).17
The introduction of a biosimilar drug into clinical
practice is based on the successful outcome of an exam-
ination conducted by the regulatory agencies, sufficient
to permit its use for the registered indications. In detail,
the so-called ‘comparability exercise’ is an experimental
procedure, requested for approval by regulatory agen-
cies.12 In the comparability exercise, the biosimilar drug
is compared with the originator drug, at a physico-
chemical level, a preclinical level and a clinical level
(usually with the conduction of randomised trials).
Clinical trials are usually designed with a study popula-
tion and clinical end points which are considered to be
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the most sensitive at highlighting any differences there
may exist between the originator and the biosimilar
drug. Of note, the aim of the comparability exercise is
not the demonstration of the efficacy in itself of the bio-
similar drug; rather, its aim is the demonstration of the
comparability of the biosimilar, with respect to the ori-
ginator, in terms of quality, efficacy and safety, given that
the efficacy of the drug has been already demonstrated
by the originator. Incidentally, it must be said that the
comparability exercise is also requested to the originator,
even after marketing, in order to authorise subsequent
‘versions’ of the drug, should the production process
undergo changes.
The AIOM working group agreed that the positive
outcome of the comparability exercise should imply con-
fidence in the substantial therapeutic equivalence
between the biosimilar drug and the originator drug,
and the subsequent application of the biosimilar drug,
to allow cost-savings. Regulatory agencies underline that
the comparability exercise is sufficient for the demon-
stration of equivalent activity, efficacy and toxicity with
respect to the originator drug. Of course, it should be
recognised that the ‘extrapolation’ from one indication
to another (in terms of different stages, different types
of disease or different association with other drugs)
between the clinical trial performed in the comparability
exercise and the use in clinical practice may be particu-
larly critical in terms of acceptability by the scientific
community.18 19
Should public bodies (regulatory authorities, scientific
societies, cooperative groups) consider a priority to invest
resources in direct comparisons (postmarketing) between
biosimilars and originators?
The AIOM working group considered that, once the
comparability exercise has led to the approval of a biosi-
milar drug for use in clinical practice, a wide use of bio-
similars in clinical practice should be recommended.
Previous experience with supportive drugs (the first
category of biosimilar drugs introduced into clinical
practice) has shown that, despite regulatory decisions,
‘trust’ by doctors in the equal efficacy of the biosimilar
drug and the originator—and the consequent use of
biosimilar drugs in clinical practice—may be scarce.20 21
At least in principle, postmarketing trials designed to
compare biosimilar drugs with originator drugs would
have the merit of increasing the level of trust in biosimi-
lars by the oncological community. This could be par-
ticularly true at the beginning, when biosimilars are not
readily and widely accepted, unless there are no adminis-
trative directives. As explained above, a particularly crit-
ical condition is the extrapolation from one indication
to another. However, the panel acknowledges that these
trials could not be realistically designed following the
strict methodological criteria used for testing a new
drug, where a formal demonstration of efficacy com-
pared with the standard treatment is required. In fact,
this would imply a very large number of patients and a
very large amount of financial resources that would rep-
resent a disappointing obstacle to the development of
biosimilars. Consequently, the priority in the investment
of resources by public bodies (regulatory authorities, sci-
entific societies, cooperative groups) in postmarketing
trials designed to directly compare a biosimilar drug and
the originator drug is rather low compared with the pri-
ority of trials comparing different drugs (table 2).
SAME THERAPEUTIC INDICATION, DIFFERENT DRUG WITH
SAME OR DIFFERENT MECHANISM OF ACTION
The availability in clinical practice of drugs with differ-
ent mechanisms of action, even in the absence of a
direct comparison, is often useful from a clinical per-
spective (due to the possibility of sequential use in dif-
ferent lines of treatment, as well as to different toxicity
profiles). On the other hand, in most cases, the panel-
lists agreed that the co-presence on the market of differ-
ent drugs with the same mechanism of action is less
justified, unless there are radical differences in the tox-
icity profile (which permit the choice of one treatment
or another, depending on the patient). In certain cases,
however, even if the drugs belong to the same class and
therefore have the same mechanism of action, they have
pharmacological differences which, at least in principle,
could lead to a different efficacy. Conversely, the plausi-
bility of a different efficacy between the treatments
under consideration becomes lower as the pharmaco-
logical differences diminish.
Table 1 Different scenarios of therapeutic equivalence
Therapeutic
indication
Mechanism
of action Active principle Example
Scenario 1 Same Same Same Generic imatinib vs brand
Scenario 2 Same Same Different, biosimilar Biosimilar filgrastim vs originator; biosimilar trastuzumab vs
originator
Scenario 3 Same Same Different Erlotinib vs gefitinib vs afatinib as first-line treatment for
EGFR-mutation positive advanced NSCLC
Scenario 4 Same Different Different Axitinib vs everolimus as second-line treatment for clear-cell
renal cancer
EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer.
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How to choose among different drugs approved in the
same setting, in the absence of a direct comparison?
In principle, the AIOM working group emphasised that
randomised trials in which the control arm is not the
best treatment available in clinical practice should never
be conducted. However, it is a fact that the regulatory
authorities can be in the position of approving a new
drug that has not been compared with the other drug
(or drugs) currently available for the same indication,
but it has been compared with the previous standard
(which, for instance, may have been the standard at the
time of trial design and/or conduction). Such situations
of ‘parallel’ development of new drugs have arisen and
probably will continue to arise, in some cases ‘justified’
by reasons linked to ‘time frames’ preceding the intro-
duction of a drug into clinical practice and, in other
cases, as a result of geographical differences in the avail-
ability of the drugs.
In principle, a coordination of different programmes
of clinical research, instead of the parallel development
of similar drugs, by means of a project shared among
several pharmaceutical companies, and ‘flexible’ over
time (in order to optimise the inclusion of new drugs
and the process of selection), would be optimal. Of
course, such a scenario would imply a robust strategic
and coordinating role played by the regulatory author-
ities. For instance, the model being developed by the US
Food and Drug Administration and the National Cancer
Institute, with the involvement of several pharmaceutical
companies, in the so-called master protocol, specifically
designed for lung cancer, could be ‘exportable’ into
other settings.22 Such coordinating programmes can be
designed to allow the parallel development of drugs
with different targets, but they could ideally allow also
an early comparison of drugs for the same therapeutic
indication, in order to select the best treatment to intro-
duce in clinical practice. Unfortunately, this ideal
coordination among development programmes for dif-
ferent drugs seems quite difficult to accomplish in prac-
tice, and drugs will probably continue to be introduced
in clinical practice without direct comparison with the
possible alternatives.
In the absence of trials designed to compare the dif-
ferent therapeutic strategies, it is necessary to perform
indirect assessments, which however are highly arbitrary,
lack recognised methodological standards for the assess-
ment of their quality and consequently produce evi-
dence of questionable reliability.
How reliable are indirect comparisons (eg, network
meta-analyses), which are often the only available
comparison among different treatments for the same
indication?
When more than one treatment has been used and
compared, either head-to-head or indirectly, in the same
clinical setting, network meta-analyses (also known as
multiple treatment comparison meta-analyses or mixed
treatment meta-analyses) offer a technical methodology
to compare the relative effectiveness of all included
interventions, allowing to synthesise and interpret all the
available evidence.23–25
The AIOM working group considered that indirect
comparisons are, in many cases, unreliable. As a general
rule, when assessing the ratio between benefits and risks
of the individual treatments available, the results of
simple mathematical exercises (such as network
meta-analyses), even if conducted with a technically
correct procedure, should be less relevant compared
with a detailed methodological and clinical analysis of
existing evidence.
Differently from ‘traditional’ meta-analyses, network
meta-analyses, by definition, are not restricted to com-
bining the results of studies which directly compared
treatment A with treatment B, but rather they compare
Table 2 Priority of resource investment by public bodies in clinical trials testing direct comparison between different drugs
approved for the same indication
Scenario
Priority of investment
of resources in direct
comparison trials Comment
Biosimilar drugs Low The conduction of postmarketing trials comparing biosimilar and
originator is a low priority, although it would increase the degree of
‘trust’ of the scientific community in the efficacy of the biosimilar
drug.
However, the panel believes that the positive results of the
comparability exercise are sufficient to recommend a wide use of
biosimilar drugs in clinical practice.
Same indication, same
mechanism of action
Variable The smaller is the plausible difference between the treatments in
question, the lower the priority of resource investment in direct
comparisons.
Same indication, different
mechanism of action
High Priority depends on the clinical relevance and on the economic
relevance (price difference between the drugs) of the unresolved
clinical problems, and on the cost that would be involved in
conducting such studies.
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the results of two or more treatments, combining studies
which have a common treatment arm.24 From a meth-
odological point of view, such meta-analyses represent a
potentially dangerous tool, because their conduction
(and publication) risks to dress with methodological
rigour and objectivity comparisons that remain weak
and scientifically debatable. In particular, if a network
meta-analysis combines the HRs from different studies,
such HRs will be strongly conditioned by the duration of
enrolment and of follow-up in single studies, and also by
the mechanism of action of one treatment with respect
to the other. For example, a network meta-analysis could
be conducted to formally quantify the difference in effi-
cacy between drug A, which produces a median survival
advantage roughly distributed across the entire study
population, and drug B, which although not significantly
altering the median survival, determines a relevant
increase in the percentage of long-term survivors. It is
clear that such a network meta-analysis would produce
distorted results and would be difficult to interpret.
Therefore, the panel emphasised that indirect compari-
sons, albeit useful in hypothesis generation, should not
be mere and misused mechanical exercises which,
though ‘formally’ correct, may be misleading from a
clinical point of view. Instead, indirect comparisons
between different drugs available for the same indica-
tion should be an exercise at the highest scientific level,
in which statistical and clinical skills are integrated in an
attempt to examine the distribution of the effects of the
various treatments. Therefore, the difference in medial
survival, the percentage of participants alive at a specific
time point and the HR itself may be insufficient, espe-
cially if taken singly, while more complex assessments
are necessary. In general, the ‘network’ meta-analysis
should serve as support, and not as a decisional tool to
sanction on the superiority of one treatment rather than
another.
Considering the above described limitations, the inter-
pretation of the indirect comparisons should be limited
to the discussion of any medium–large differences,
ignoring the statistical significance and differences of
modest clinical relevance, in which the weight of com-
parison bias may be greater than the real difference
between the treatments under study.
Should public bodies (regulatory authorities, scientific
societies, cooperative groups) consider a priority to invest
resources in direct comparison (postmarketing) between
different drugs available for the same indication?
In general, given the substantial limitation of indirect com-
parisons (as described in the previous paragraph), the
AIOM working group judged the conduction of clinical
trials directly comparing different drugs for the same indi-
cation as a priority. Such trials aim to increase scientific evi-
dence, and optimise therapeutic choices in clinical
practice. The priority for resource investment in direct
comparisons depends on the clinical relevance and on the
economic relevance (difference in price between the
drugs) of any unresolved clinical issues (table 2). The
larger is the possible or actual difference between the
treatments, the higher the priority of resource allocation
for direct comparison. The priority for investing resources
in a direct comparison between drugs with the same mech-
anism of action is necessarily lower. However, even if the
drugs belong to the same class, if the difference that can
be assumed (on the basis of indirect comparisons and of
pharmacological differences) is potentially relevant, then
the priority could be higher.
After the approval of a new drug for use in clinical
practice, it is obviously not realistic that pharmaceutical
companies will promote further trials that would chal-
lenge the indication already obtained. Consequently, the
conduction of these trials should be a priority for aca-
demic research that has the aim of optimising thera-
peutic decisions in clinical practice. Although we are
aware that the availability of funding for this research
can be really difficult, the panel strongly believes that
public bodies (regulatory agencies, scientific societies,
cooperative groups) should encourage and support, with
dedicated funds and calls for projects, the conduction of
these trials.
How should a direct comparison be designed?
The general answer is relatively simple: when several
drugs have been approved for the same indication, but
not yet directly compared, the choice of the study
design (superiority or non-inferiority design) depends
on the comparison between the toxicity profiles (which
is grossly possible a priori, even in the absence of a
direct comparison) and also depends on the differential
efficacy (which, in the absence of a direct comparison, is
necessarily only ‘presumed’; figure 1).
When it is plausible to assume similar efficacy (or
small differences in efficacy between the treatments), it
will be the more toxic drug that needs to demonstrate,
within a direct comparison, a greater efficacy, that will
justify its use despite the excess of toxicity. In this case, it
is correct to consider a superiority design: the less toxic
treatment will be the reference (control) arm, while the
more toxic treatment will be the experimental arm.
Necessarily, the greater the difference in toxicity, the
greater will be the threshold of the increase in efficacy
which must be demonstrated to declare the superiority
of the experimental arm. In the case of a negative
result, the less toxic drug will remain preferable as the
standard in clinical practice. As for other superiority
trials, the threshold of increased efficacy—either as a
relative or an absolute benefit—that would determine
the preference for the more toxic treatment, is clearly
dependent from the specific clinical setting, in terms of
patients’ prognosis and toxicity profile of the drugs, and
should be clearly discussed in the study protocol. When
the toxicity is high, even a potentially relevant difference
in survival could not be enough to convince clinicians
and patients to use the more toxic strategy. On the
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contrary, the same difference could be sufficient if the
toxicity, although more relevant, is considered
manageable.
On the other hand, if it is plausible that the more
toxic drug is also associated with a greater efficacy, the
aim of a direct comparison will be to demonstrate that
the use of the less toxic drug is not associated with a
‘clinically relevant’ loss of efficacy. Therefore, in this
case, it will be correct to consider a non-inferiority
design, in which the more toxic treatment will be the
reference arm, and the less toxic treatment will be the
experimental arm. If the study is negative (ie, non-
inferiority not demonstrated), the more toxic drug will
remain preferable as the standard in clinical practice.
However, it is useful to underline that, as a general rule,
non-inferiority trials should only be conducted when the
experimental treatment presents clear advantages for
the patient (eg, a lower toxicity, or a more suitable
administration route) or for the community (as in the
case of biosimilars) without any predictable damage for
the patients. In the absence of such advantages, a non-
inferiority trial loses its rationale, and it becomes ethic-
ally unacceptable. Of note, the extent of such advan-
tages is relevant for the study design, in that it enables
to determine the acceptable margin of non-inferiority. It
is particularly difficult to propose a general rule for the
definition of margins of non-inferiority, because this def-
inition is necessarily related to each specific clinical
scenario. Clinical reasons for the definition of margins
of non-inferiority should be clearly discussed in the
study protocol, based on the prognosis of patients, tox-
icity of treatments considered and the absolute benefit
that the more toxic treatment has demonstrated com-
pared with the previous standard. A potential loss of
2 months in median survival with the less toxic of two
treatments can be clinically acceptable, if the difference
in toxicity is large and if the absolute benefit previously
demonstrated by the more toxic treatment is 5–
6 months. On the contrary, the same potential loss of
2 months in median survival would be obviously
unacceptable, even in the presence of a large difference
in toxicity, if the absolute benefit of the more toxic treat-
ment is lower than 3 months.
If the drugs being compared are both approved for
clinical practice, there could be confusion in the inter-
pretation of results, related to cross-over. In fact, many of
these studies should be designed (and interpreted) as
studies of treatment sequences rather than ‘simple’ com-
parisons of two different single lines of treatment.
In particular cases, especially with rare diseases, when
the toxicity profiles are qualitatively very different while
the efficacy appears, at least on the basis of indirect com-
parisons, roughly superimposable, an observational
study could be more feasible than a randomised com-
parison. In this case, the choice of treatment could be
left to the patient, on the basis of the toxicity profile
(while randomisation could be performed just for those
patients who are uncertain about the choice), and the
analysis of clinical outcomes in the different treatment
groups would add evidence useful for future patients.
CONCLUSIONS
In many clinical settings, clinical trials comparing differ-
ent treatment options for the same therapeutic indica-
tion would produce important evidence, allowing better
decisions in clinical practice. As expected, most of these
trials are not part of the development of drugs aimed at
their registration, and their conduction could be part of
the postregistration phase.
Figure 1 Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different
treatments for the same therapeutic indication, based on the presumed difference in efficacy and on the toxicity profiles.
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With this position paper, the panel of clinicians and
methodologists of the Italian Association of Medical
Oncology emphasise the need for supporting this aspect
of clinical research. In addition, the panel suggests pri-
orities in the allocation of financial resources for the
conduction of these non-profit trials by public bodies
(regulatory agencies, scientific societies, cooperative
groups). In the absence of previous direct comparisons,
the larger the potential difference between the existing
therapeutic options, the higher is the priority for the
conduction of these trials. Of course, the feasibility of
these trials will depend on the cost involved in their con-
duction. From this point of view, scientific societies
should put pressure on the regulatory authorities, to
identify all the administrative and financial mechanisms
useful to facilitate the conduction of such trials, limiting
costs as much as possible.
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